Imperative Care Launches CLEAR-IT Peripheral Thromboembolism Study

March 25, 2025—Imperative Care, Inc. announced the enrollment of the first patient in the prospective observational CLEAR-IT clinical study evaluating the performance of the company’s Symphony and Prodigy systems, which are aspiration-based technologies used in endovascular thrombectomy procedures across the peripheral and pulmonary vasculature.

According to Imperative Care, the CLEAR-IT study is expected to enroll up to 750 patients across up to 50 sites in the United States. It will evaluate the short- and long-term clinical performance and safety of Symphony and Prodigy.

By assessing outcomes in pulmonary embolism, peripheral venous thrombosis, and peripheral arterial thrombosis, the study will evaluate procedural characteristics and patient outcomes in a real-world setting with the goal of contributing evidence to inform the development of clinical standards for the treatment of these conditions, advised Imperative Care.

The study is led by Principal Investigators Steven Abramowitz, MD, and Maya Serhal, MD. Dr. Abramowitz is Chief of Vascular Surgery at MedStar Hospital in Washington DC. Dr. Serhal is an interventional cardiologist and vascular interventionalist at Massachusetts General Hospital in Boston, Massachusetts.

“CLEAR-IT is designed to evaluate how Symphony and Prodigy perform across a broad range of peripheral thromboembolic conditions in real-world clinical practice,” commented Dr. Abramowitz in the Imperative Care press release. “This study is structured to drive clinically meaningful endpoints that matter to physicians and patients. By generating high-quality data across multiple disease states, we believe the CLEAR-IT study can move the field closer to establishing clear clinical standards for the treatment of each of these respective diseases.”

The first patient enrolled in the study was treated by Dana Tomalty, MD, who serves as the site Principal Investigator at Huntsville Hospital Health System in Huntsville, Alabama.

“Following the SYMPHONY-PE investigational device exemption trial, which demonstrated favorable safety and efficacy results, initial real-world experience with this technology has shown fast, effective clot removal with minimal blood loss,” stated Dr. Tomalty in the press release. “We look forward to contributing to independently adjudicated clinical data that have the potential to further advance the field and support more informed clinical decision-making for patients with thromboembolic disease.”